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Results: BI 2536 potently inhibited proliferation of NSCLC cell lines 
with EC50 values of 8 - 14 nM. The compound showed good anti-tu-
mor activity in vivo in all 4 NSCLC xenograft models tested with T/C 
(“treated/control”) values of 1% (Calu-6), 14% (A549), 21% (NCI-
H460), and 41% (NCI-H520TC) at doses that were well tolerated. Im-
munohistochemical analysis of NCI-H460 tumors excised from treated 
animals as well as near-infrared optical imaging using Cy5.5-coupled 
annexin V demonstrated mitotic arrest and induction of apoptosis in 
vivo. Combination therapy with established chemotherapeutic agents 
(cisplatin, docetaxel or pemetrexed) resulted in improved efﬁcacy in 
the absence of additional toxicity. 
Conclusion: BI 2536 is a potent inhibitor of NSCLC cell prolifera-
tion in vitro and shows efﬁcacy in multiple human NSCLC xenograft 
models at well-tolerated doses. Combination therapy with BI 2536 and 
established chemotherapeutic agents is well tolerated and results in 
improved efﬁcacy compared to single-agent treatment. 
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Background: ING genes (Inhibitor of Growth, ING1-5) are candidate 
tumor suppressor genes which have been recently identiﬁed and charac-
terized. Whereas ING1 expression has been shown to be down-regulat-
ed in several tumor types through a yet unknown mechanism (mutation 
of the gene is a rare event), few data have been reported regarding the 
status of other members of the family. ING2 is involved in tumor sup-
pression pathways such as apoptosis and senescence. It is a chromatin 
associated protein, a nuclear phosphoinositide receptor which interacts 
with trimethylated H3 on lysine 4 and can regulate p53 transcriptional 
activity by enhancing its acetylation to modulate cellular response to 
genotoxic stress. ING2 status in human tumors is still unknown (one 
study reported the reduced expression of ING2 in melanoma) and its 
role and regulation in carcinogenesis are poorly understood.
Methods: We investigated the involvement of ING2 in human lung 
tumors by analyzing ING2 protein expression on tumors and their 
related normal tissues (this study was done on samples from the tumor 
bank (CRB, Grenoble) and with tumor tissue micro-arrays. Immunohis-
tochemical analysis was performed on 75 formalin ﬁxed tumor tissues 
and normal counterpart using speciﬁc ING2 polyclonal antibody KMP1 
(kindly provided by Dr. C. Harris) dilution 1/100. Score of immunos-
taining (0-300) was established by multiplicating the percentage of 
stained cells (0-100) by intensity (1-3). Cut-off of score for discrimi-
nating positive from low expression and negative was determined by 
the mean level of expression on normal alveolar cells taken as internal 
control (mean 120): score of 0 to 50 considered as negative; 50 to 
120 as low and >120 as positive. mRNA were extracted by Trizol and 
analyzed by RT-PCR.
Results: A strong and mainly (but not exclusively) nuclear staining of 
ING2 was detected in normal lung tissues, mostly in Type II pneu-
mocytes. In non-small cell lung cancers, a loss or low level of ING2 
expression was observed in 75 % (27/36) adenocarcinoma and 82 % 
(32/39) squamous cell carcinoma as compared with normal lung. Fur-
thermore, in many cases, the ING2 nuclear staining was lost; whereas, 
the cytoplasmic staining was maintained. These results suggest that 
in tumor cells ING2 could be excluded from the nucleus. Analysis of 
mRNA expression by real-time PCR of 13 tumors and corresponding 
normal lung tissues showed a marked decrease of the mRNA in tumors. 
Since ING2 promoter contains several CpG islands, methylation of the 
promoter in these tumors is being investigated.
Conclusion: Taken together, these results suggest that ING2 could be 
inactivated in lung tumors either by downregulation at the mRNA level 
or exclusion of the protein from the nucleus. Further analysis of these 
tumors, especially their p53 status should help us to understand the role 
ING2 could play in lung carcinogenesis.
Rémy Pedeux was a recipient of a research grant from IASLC (2005-
2007).
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Background: Radiation dose escalation might improve local control 
in NSCLC, but is associated with increased toxicity. Consequently 
patients have to be selected carefully to prevent, both over- and under-
treatment. As part of a prospective clinical trial we reported that meta-
bolic responders and non-responders (EORTC-criteria) showed differ-
ent time trends in maximal SUV (standardized uptake value, SUVmax) 
of 18F-FDG on PET-scan. Moreover, metabolic responders showed an 
improved overall survival compared to non-responders (van Baard-
wijk et al., Radioth Oncol 2007). The aim of the current study was to 
investigate changes in plasma levels of cytokines and the association 
of these changes with SUVmax and the amount of toxicity during and 
after radiotherapy (RT), to further unravel underlying mechanisms.
Methods: From 21 patients included in the clinical trial, repeated 
plasma samples (n=67) were collected before RT, on day 7 and 14 
during RT and 70 days after RT. Levels of IL-1b, IL-5, IL-6, IL-8, 
IL-10, TNF-α, M30, M65, osteopontin and neopterin were assessed 
using ELISA’s. Unmeasurable levels were assumed to be zero. Levels 
of cytokines were associated with SUVmax of FDG-PET and toxicity 
score, according to CTCAE-criteria. Moreover, changes in levels of 
cytokines between the different time points during RT (day 0 versus 
day 7, day 7 versus day 14) were correlated with changes in SUVmax 
within the same time-interval. Results are expressed as mean ± SEM. 
Pearson correlation coefﬁcient and Mann Whitney U-test were used to 
analyze the data. 
Results: A large heterogeneity in evolution in cytokine levels during 
RT was observed between individual patients. It was shown that chang-
es in SUVmax correlated with changes in the level of IL-6, showing a 
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correlation coefﬁcient of 0.51 for the change between day 0 and day 7 
(p=0.02) and of 0.59 for the change in the second week of RT (day 7 
and 14, p=0.02). This correlation was not observed for other cytokines. 
Moreover, IL-6 levels were higher in patients showing no metabolic 
response compared to responders: day 0 resp. 18.9 ± 7.6 and 6.0 ± 0.9 
(p=0.06), day 7 resp. 31.0 ± 13.0 and 9.5 ± 3.0 (p=0.03) and for day 14 
resp. 25.3 ± 12.2 and 8.5 ± 1.9 (p=0.10). Seventy days after RT, levels 
of IL-1b (r=-0.55, p=0.04) as well as neopterin (r=0.58, p=0.04) were 
positively correlated with clinically symptomatic pneumonitis (>grade 
1). Furthermore, the dyspnea score at this time point showed a graded 
correlation with plasma levels of neopterin (r=0.76, p<0.01) and the 
cough score with osteopontin levels (r=0.81, p<0.01), while these phe-
nomena were not observed during RT. 
Conclusions: Changes in SUVmax were positively correlated with 
changes in IL-6 levels during radiotherapy, suggesting that changes 
in FDG uptake might be partly explained by inﬂammation. Seventy 
days after radiotherapy, levels of neopterin were correlated with both 
symptomatic pneumonitis and dyspnea score, assuming cell-mediated 
immune activation in the development of pneumonitis. Furthermore, 
levels of osteopontin, a lungﬁbrosis related protein, were correlated 
with cough score after radiotherapy.
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Background: While standard chemotherapy for non-small cell lung 
cancer (NSCLC) confers a survival beneﬁt to patients and improves 
quality of life, a complete response to therapy is uncommon, especially 
for patients with advanced disease. Uncovering genomic signatures 
that predict drug response for speciﬁc tumors will allow for the rational 
selection of effective treatments for individual patients and lay the 
foundation for personalized treatment strategies.
Objective: To determine if genomic features present in pre-treatment 
tumor cells can predict response to chemotherapy and to identify novel 
genes associated with drug resistance.
Methods: A panel of archived pre-treatment lung tumor biopsies with 
recorded patient response to a standard doublet regime (cis-platinum/
vinorelbine) were selected and subdivided into “responders” and “non-
responders” based on clinical parameters. Following pathology review, 
tumor cells were isolated and DNA was extracted from formalin-ﬁxed, 
parafﬁn-embedded tissue sections. Molecular proﬁling of tumors was 
undertaken by whole genome tiling-set array comparative genomic hy-
bridization (aCGH). The SeeGH and SIGMA software programs were 
used for visual analysis of all aCGH proﬁles. A segmentation algorithm 
was applied to array data to identify DNA copy number alterations in 
each tumor. Statistical analysis of processed tumor genome data was 
used to deﬁne regions of signiﬁcant difference between the “responder” 
and “non-responder” subgroups.
Results: Comparative analysis of high resolution genome proﬁles for 
“responder” and “non-responder” tumors revealed segmental genomic 
gains and losses speciﬁc to each group. Genes within these regions 
of alteration are known to play a role in cellular processes that affect 
response to chemotherapeutic agents, including DNA repair and apop-
totic signalling. Functional experiments for candidate loci are ongoing.
Conclusions: High resolution analysis of pre-treatment tumor genomes 
reveals molecular signatures that can predict response to chemotherapy. 
Clinical application of such signatures will allow cancer treatments to 
be tailored to individual patients. In addition, candidate response genes 
within identiﬁed signatures may provide insight into drug resistance 
mechanisms and serve as novel therapeutic targets.
Funding for this work was provided by Genome Canada/Genome BC 
and Amgen, Inc.
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Background: Tobacco smoke is strongly correlated with lung carcino-
genesis, particularly for squamous cell carcinoma (SqCC). In addition 
to tobacco smoke, exposure to arsenical compounds in drinking water 
has also been strongly related to increased incidence of lung cancer, 
particularly SqCC.
In the northern part of Chile (Antofagasta City), the population has 
been chronically exposed to arsenic compounds in drinking water 
at high concentrations. Antofagasta shows the highest incidence 
(39.4/100,000 inhabitants) and mortality (33.3/100,000 inhabitants) 
rates for lung cancer in the country. Almost 70% of diagnosed cases are 
of the SqCC. However, the prevalence of smoking in Antofagasta is not 
greater relative to the rest of the country (approximately 20% smokers 
by population).
The purpose of this study is to compare DNA segment copy number 
changes in lung SqCC from patients with and without exposure to 
arsenic and or tobacco smoke to determine pathways that are unique to 
arsenic induced lung cancer. We also want to determine pathways that 
are common in the carcinogenesis process irrespective to the type of 
carcinogen exposure.
Methods: A panel of 13 parafﬁn-embedded lung SqCC was collected 
from the Hospital of Antofagasta on the basis of patient residence, more 
than 15 years living in the region prior to diagnosis, and no history of 
previous cancer. We divided this group in smokers (S-As group) and 
non-smokers (nonS-As) Twenty-one tumors from non-arsenic ex-
posed patients (S-noAs) were collected from British Columbia Cancer 
Agency (Canada) for comparison. Genomic proﬁling was performed 
by high resolution tiling path array comparative genomic hybridization 
(CGH). The SeeGH software was used for alignment and analysis of 
all array CGH proﬁles. Genomic regions with p-values less than 0.05 
(Fisher exact test) were used for analysis.
Results: Alterations in NS-As group are much lower than the other two 
groups. Overall, the frequency of alteration in 3q (the most consistently 
over-represented region in SqCC related to tobacco smoking) in nonS-
As group is lower than in smokers. We also found genomic regions 
with a high degree of similarity between S-noAs and NS-As e.g. losses 
at 6q16.1-3, 9q33.1-2 10q11.21 and gains at 12p12.3
NS-As group shows a statically signiﬁcantly higher frequency of 
copy number gains of a 4 Mb segment at 19p12. The same region is 
